Moclobemide Explained

Verifiedfields:changed
Verifiedrevid:457784738
Iupac Name:4-chloro-N-(2-morpholin-4-ylethyl)benzamide
Width:250
Width2:225
Tradename:Amira, Aurorix, Clobemix, Depnil, Manerix, others
Pregnancy Au:B3
Legal Au:S4
Legal Br:C1
Legal Br Comment:[1]
Legal Ca:Rx-only
Legal Uk:POM
Routes Of Administration:By mouth
Bioavailability:55–95% (increases with repeat administration)
Protein Bound:50%[2]
Metabolism:Liver
Elimination Half-Life:1–2 hours, 4 hours (elderly)[3] [4]
Excretion:Kidney, Faecal (<5%)
Iuphar Ligand:7428
Cas Number:71320-77-9
Atc Prefix:N06
Atc Suffix:AG02
Pubchem:4235
Drugbank:DB01171
Chemspiderid:4087
Unii:PJ0Y7AZB63
Kegg:D02561
Chebi:83531
Chembl:86304
C:13
H:17
Cl:1
N:2
O:2
Smiles:Clc1ccc(cc1)C(=O)NCCN2CCOCC2
Stdinchi:1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
Stdinchikey:YHXISWVBGDMDLQ-UHFFFAOYSA-N

Moclobemide, sold under the brand names Amira, Aurorix,[5] Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the UK and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.

No significant rise in blood pressure occurs when moclobemide is combined with amines such as tyramine-containing foods or pressor amine drugs, unlike with the older irreversible and non-selective monoamine oxidase inhibitors (MAOIs), which cause a severe rise in blood pressure with such combination. Due to the lack of anticholinergic, cardiovascular, cognitive and psychomotor impairments moclobemide is advantageous in the elderly as well as those with cardiovascular disease.

Medical uses

Reversible selective MAOIs such as moclobemide are underprescribed due to the misconception that the side effect profiles are analogous to that of the irreversible and non-selective MAOIs. MAOIs such as moclobemide are reported to have a relatively fast onset of action compared to other antidepressant drug classes,[6] and have good long-term tolerability in terms of side effects.

Tolerance does not seem to occur; research has found that moclobemide retains its beneficial therapeutic properties in depression for at least a year.[7]

Psychotic depression, unipolar endogenous depression, melancholic depression, retarded depression, agitated depression and neurotic depression all respond to moclobemide,[11] as does atypical depression.[12] Unipolar endogenous depression is reported to have the best response to moclobemide therapy.[13] [14] Individuals suffering from depression who are given moclobemide are twice as likely to improve on moclobemide than on placebo.[15] A concern of antidepressant adverse effects is sexual dysfunction; however, moclobemide has been found to actually increase libido and improve impaired erection, ejaculation and orgasm.[16] Cardiovascular toxicity is a concern with antidepressants such as tricyclic antidepressants as well as the irreversible MAOIs; when cardiovascular toxicity is a concern, SSRIs or the reversible MAOIs such as moclobemide are an option as they lack or have a significantly reduced level of cardiovascular toxicity in terms of adverse effect as well as in overdose.[17]

The effectiveness of moclobemide in agitated depression is equivalent to that of imipramine and sedative antidepressants such as amitriptyline, mianserin and maprotiline. The therapeutic response in agitated depressive individuals is similar to that seen in non-agitated depression; however, a past history of use of antidepressants reduces the chance of successful therapeutic response. The addition of a benzodiazepine to moclobemide therapy has not been found to be of benefit in this population group.[18] Moclobemide has better tolerability compared to TCAs.[19]

Similar to other MAOIs, reversible MAOIs such as moclobemide may also be effective in a range of other psychiatric disorders.[11] [31] Menopausal flushing may also respond to moclobemide.[32]

In efficacy studies for the treatment of major depressive disorder, moclobemide has been found to be significantly more effective than placebo, as effective as the tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), and somewhat less effective than the older, irreversible MAOIs phenelzine and tranylcypromine. In terms of tolerability, however, moclobemide was found to be comparable to the SSRIs and better tolerated than the TCAs and older MAOIs.[33] There is some evidence that moclobemide on its own or in combination with other antidepressants such as SSRIs is also effective for treatment resistant depression and that the combination can be administered without the development of serotonin syndrome; however, further research is needed before such a combination can be recommended.[34] Follow-up studies show that ongoing use of antidepressants leads to continuing improvement in depression over time; and also have demonstrated that moclobemide retains its therapeutic efficacy as an antidepressant for at least a year. This long-term efficacy is equivalent to that seen with other antidepressant classes.[35]

People on irreversible MAOIs have to discontinue these antidepressants two weeks before general anesthesia, however, the use of moclobemide, due to its reversible nature, would allow such patients to possibly continue antidepressant therapy.[36] [37]

A dexamethasone suppression test (DST) and plasma and urine methoxyhydroxyphenylglycol (MHPG) test can be used to estimate who is likely to respond to moclobemide antidepressant therapy.[38]

Pregnancy and lactation

The doses of moclobemide in breast milk are very low (0.06% of moclobemide being recovered in breast milk) and therefore it has been concluded that moclobemide is unlikely to have any adverse effect on a suckling baby.

Children

Use in children is not recommended as there is insufficient data to assess safety and efficacy in these patients.[25]

Elderly

Reversible MAOIs such as moclobemide may have advantages in the treatment of depression associated with Alzheimer's disease due to its effect on noradrenaline.[39] Cognitive impairments have been found to improve in people with dementia when depression is treated with moclobemide.[11] Due to its superior safety profile, moclobemide has been recommended as a first line agent for the treatment of depression in the elderly.[40] Due to the side effect profile of moclobemide, it may be a better option for this sub group of people than other antidepressants.[41] Research has found evidence that moclobemide may be able to counter anti-cholinergic (Scopolamine) induced cognitive impairments thus making moclobemide a good choice in the depression in the elderly and those with dementia.[42]

Adverse effects

The incidence of adverse events is not correlated with age; however, adverse events occur more often in females than in males.[43] Moclobemide is regarded as a generally safe antidepressant and due to its favorable side effect profile, it can be considered a first-line therapeutic antidepressant.[44] The rate of incidence of side effects of moclobemide is low,[45] with insomnia, headache and dizziness being the most commonly reported side effects in the initial stages of therapy with moclobemide.[46] Moclobemide, even at high doses of 600 mg, does not impair the ability to drive a motor vehicle. The tolerability of moclobemide is similar in women and men and it is also well tolerated in the elderly.[47] Moclobemide has been found to be superior to tricyclic and irreversible MAOI antidepressants in terms of side effects, as it does not cause anticholinergic, sedative or cardiovascular adverse effects.[48]

Unlike the irreversible MAOIs there is no evidence of liver toxicity with moclobemide.[49] Moclobemide has a similar efficacy profile compared to other antidepressants while being superior to the classic MAOIs and the tricyclics in terms of tolerance and safety profile.[50] Moclobemide has little effect on psychomotor functions. Other side effects include nausea, insomnia, tremor and lightheadedness; orthostatic hypotension (dizziness upon standing) is uncommon even among the elderly.[33] Behavioural toxicity or other impairments relating to everyday living does not occur with moclobemide, except that in doses of 400 mg or higher peripheral reaction time may be impaired.[51] Peripheral oedema has been associated with moclobemide.[52]

Some of the side effects are transient and disappear within 2 weeks of treatment.[53] Serious fatigue, headache, restlessness, nervousness and sleep disturbances have been described as side effects from moclobemide therapy.[54] A paradoxical worsening of depression has been reported in some individuals in several studies,[55] and reports of suicide or suicidal ideation have been reported as a rare adverse effect of moclobemide.[56] Overall, antidepressants decrease the risk of suicide.[57] Moclobemide is believed to have only small proconvulsant effects;[58] however, rarely seizures may occur.[59] Hypertension has been reported to occur very rarely with moclobemide therapy.[33]

Moclobemide is relatively well tolerated. The following are the potential adverse effects and their respective incidences:[60] [61]

Common (>1% incidence) adverse effects
Uncommon/Rare (<1%) adverse effects

Contraindications

Avoid use in:[25]

and caution is recommended in:[62]

Interactions

DrugMoclobemide has fewer interactions than irreversible MAOIs. Cimetidine however, causes a significant rise in moclobemide levels and therefore if the combination is used, lower doses of moclobemide have been recommended.[63] There is little increase in the effects of alcohol when combined with moclobemide[63] and, in fact, moclobemide causes a reduction in alcohol-related impairments.[64] Moclobemide also interacts with pethidine/meperidine,[65] and dextropropoxyphene.[50] Ephedrine in combination with moclobemide increases the risk of cardiovascular adverse effects.[66] Moclobemide is also likely to interact with warfarin.[67] The combination of moclobemide with prescription or over the counter sympathomimetic drugs is not recommended due to the potential of significant drug interactions.[68]

Serotonin syndrome has been reported when moclobemide has been taken in combination with other serotonin enhancing drugs; however, due to moclobemide's reversible MAO inhibition, serotonin syndrome is significantly less likely to occur with moclobemide than with older irreversible MAOIs.[69] [70] Serotonin syndrome has been reported when trazodone was abruptly replaced with moclobemide.[71] Taking at the same time or starting moclobemide too soon after discontinuing clomipramine or serotonin reuptake inhibitors such as SSRIs may result in the development of a serotonin syndrome.[50] [72] SNRIs such as venlafaxine in combination with moclobemide have also been associated with serotonin syndrome.[73] Cimetidine causes a doubling of the blood plasma levels of moclobemide. Blood plasma levels of trimipramine and maprotiline and possibly other tricyclic antidepressants increase when used in combination with moclobemide and may require dosage adjustments if the combination is used for treatment resistant depression.[74] The elimination of zolmitriptan is reduced by moclobemide and if the combination is used, a dosage reduction of zolmitriptan is recommended.[75] Moclobemide reduces the metabolism of dextromethorphan.[76] Moclobemide may decrease metabolism of diazepam, omeprazole, proguanil, propranolol and others due to inhibition of CYP2C19.[77]

DietaryIrreversible MAOIs can cause unpleasant and occasionally dangerous side effects such as a hypertensive crises after intake of food or drink containing indirectly acting sympathomimetic amines such as tyramine. This is sometimes referred to as the 'cheese effect'. These side effects are due to irreversible inhibition of MAO in the gut and vasomotor neurones. However, the reversible MAOI antidepressants such as moclobemide have a very different side effect profile in this regard. The reversible binding to MAO-A by moclobemide allows amines such as tyramine to displace moclobemide from MAO-A allowing its metabolism and removing the risk of a hypertensive crisis that occurs with irreversible MAO inhibition.[78] Of 2300 people in multiple clinical trials who were treated with moclobemide in doses up to 600 mg with no dietary restrictions, none experienced a tyramine-mediated hypertensive reaction.[47] As the pressor effect of moclobemide is so low, dietary restrictions are not necessary in people eating a normal diet, in contrast to irreversible MAOIs. However, some rare cheeses that have a high tyramine level may possibly cause a pressor effect and require caution.[79] The potentiation of the pressor effect of tyramine by moclobemide is only one seventh to one tenth of that of irreversible MAOIs.[80] In order to minimize this potentiation, postprandial administration (taken after meals) of moclobemide is recommended. The combined use of moclobemide and selegiline requires dietary restrictions as the combination can lead to increased sensitivity to the pressor effect of foods containing tyramine.[81]

While moclobemide or the irreversible MAO-B selective inhibitor selegiline taken alone has very little pressor effect, and requires no dietary restriction, the combination of selegiline with moclobemide leads to a significant enhancement of the pressor effect and such a combination requires dietary restriction of foods containing high amounts of tyramine.[82] The combination of moclobemide and a reversible MAO-B inhibitor requires tyramine dietary restrictions.[83]

Overdose

Moclobemide is considered to be less toxic in overdose compared to older antidepressants, such as the tricyclic antidepressants and the irreversible and non-selective MAOIs, making it a safer antidepressant in the elderly or people with physical disorders.[48] Of 18 people who overdosed on moclobemide during clinical trials, all recovered fully and moclobemide was judged to be safe for inpatient as well as outpatient use.[84] Intoxications with moclobemide as single agent are usually mild; however, when combined with tricyclic or SSRI antidepressants the overdose is much more toxic and potentially fatal.[85] [86] Moclobemide, is preferred by doctors for patients who are at risk of suicide, due to moclobemide's low toxicity in overdose.[87] Patients with mixed intoxications (e.g. with other CNS active drugs) may show severe or life-threatening symptoms and should be hospitalized. Treatment is largely symptomatic and should be aimed at maintenance of the vital functions.

Withdrawal and tolerance

Withdrawal symptoms appear to be very rare with moclobemide compared to other antidepressants; a single report of relatively mild flu-like symptoms persisting for 7 days after rapid reduction of high dose moclobemide therapy has been reported in one patient.[88] Withdrawal of moclobemide causes a rebound in REM sleep.

Moclobemide does not seem to prevent withdrawal symptoms from serotonin reuptake inhibitors.[89]

Discontinuation of moclobemide is recommended to be done gradually to minimise side effects (e.g. rapid return of condition being treated and/or the appearance of withdrawal symptoms). Tolerance to the therapeutic effects has been reported in a small number of users of MAOIs including moclobemide.[35]

Pharmacology

Moclobemide is a benzamide,[33] derivative of morpholine,[90] which acts pharmacologically as a selective, reversible inhibitor of monoamine oxidase-A (RIMA),[91] a type of monoamine oxidase inhibitor (MAOI), and increases levels of norepinephrine (noradrenaline), dopamine, and especially serotonin[92] [93] in neuronal cells as well as in synaptic vesicles; extracellular levels also increase which results in increased monoamine receptor stimulation and suppression of REM sleep, down regulation of beta-3 adrenergic receptors. Moclobemide's primary action is to disable MAO-A enzymes from decomposing norepinephrine, serotonin, and dopamine which results in a rising level of these neurotransmitters. Although it has been estimated that a single 300 mg dose of moclobemide inhibits 80% of monoamine oxidase-A (MAO-A) and 20-30% of MAO-B,[94] studies evaluating brain occupancy of MAO-A enzymes have shown dosages of 600 mg to only inhibit 74% of MAO-A enzymes[95] and dosages in the 900–1200 mg range to inhibit slightly less MAO-A than phenelzine (Nardil) at 45–60 mg;[96] subsequently, it is highly plausible that reports of lower efficacy[97] could be largely or entirely the consequence of conservative dosage guidelines rather than the pharmacological properties of the drug. Previously, it was widely reported that both MAO-A and MAO-B enzymes were responsible for the metabolism of dopamine; however, new research suggests that MAO-B enzymes are involved in the generation of GABA and not the degradation of dopamine.[98] There is also some evidence of moclobemide possessing neuroprotective properties in rodent models. There is no cumulative effect of moclobemide centrally when taken long-term. With long-term use of moclobemide, there is a significant down-regulation of B-adrenoceptors.[92] Single or repeated dosing with 100–300 mg of moclobemide leads to a reduction in deaminated metabolites of amines such as 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxyphenylethylglycol as well as 5-HIAA. Excretion of homovanillic acid and vanillylmandelic acid via urine is also reduced. There is also a temporary increase in prolactin during initial intake of 100–300 mg of moclobemide.[92] L-dihydroxyphenylalanine is also reduced.[99] Inhibition of the serotonin metabolite is less pronounced than the norepinephrine metabolite which suggests there are other major metabolic pathways for serotonin other than MAO-A.[100]

It has been described as a 'slow binding inhibitor', whereby conformational changes to either moclobemide or the enzyme to MAO-A slowly form a more tightly bound complex, resulting in the non-competitive MAO inhibition by moclobemide.[92] With three times daily dosing the inhibition on MAO-A was relatively constant with moclobemide.[101] The MAO inhibition of moclobemide lasts about 8–10 hours and wears off completely by 24 hours after dosing.[92] [93] The inhibition of MAO-A by moclobemide is 10 times more potent than the irreversible MAOI phenelzine and approximately equivalent to tranylcypromine and isocarboxazid.[92]

Moclobemide increases levels of extracellular monoamines and decreases levels of their metabolites in rat brains; tolerance to these effects does not seem to occur with chronic use of moclobemide. Moclobemide lacks anticholinergic effects and cognitive impairments can be improved by moclobemide.[102] Moclobemide suppresses the unstimulated release of certain proinflammatory cytokines which are believed to be involved in the pathophysiology of major depression and stimulates the release of anti-inflammatory cytokines.[103] Long-term treatment with moclobemide leads to an increase in cyclic adenosine monophosphate (cAMP) binding to cAMP-dependent protein kinase (PKA).[104]

Moclobemide is chemically unrelated to irreversible MAOI antidepressants and only has a very weak pressor effect of orally administered tyramine.[105] In humans, the n-oxide metabolites of moclobemide and moclobemide itself are the compounds that produce most of the inhibition of MAO-A; other metabolites are significantly less potent than the parent compound.[92]

In healthy people moclobemide has a relatively small suppressing effect on REM sleep; in contrast, depressed people who have been treated with moclobemide, progressively show improved sleep over a 4-week period, with an increase in stage 2 non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep.[92] There have been conflicting findings with regard to moclobemide altering cortisol levels and whether moclobemide increases growth hormone levels.[92] Testosterone levels increase significantly with long-term use of moclobemide in depressed males.[106]

Moclobemide also has neuroprotective properties in its demonstrated anti-hypoxia or anti-ischemia effects; there is a possibility that moclobemide may possess similar neuro-rescuing properties, similar to selegiline, however, research is required to determine this.[92] Moclobemide has also been demonstrated in a single dose research study to possess antinociceptive properties.[107]

Platelet MAO is of the MAO-B and this is inhibited only to a small degree in humans; the inhibition is due to low levels of metabolites of moclobemide that have MAO-B inhibiting properties.[108] Moclobemide has been reported to be a mixed MAO-A/MAO-B inhibitor in rats but in man, it has been reported to be a pure MAO-A inhibitor,[109] blocking the decomposition of norepinephrine, serotonin and, to a lesser extent, dopamine. No reuptake inhibition of any of the neurotransmitters occurs. The pharmacodynamic action encompasses activation, elevation of mood, and improvement of symptoms like dysphoria, fatigue, and difficulties in concentration. The duration and quality of sleep may be improved. In the treatment of depression the antidepressant effect often becomes evident in the first week of therapy (earlier than typically noted with TCAs/SSRIs).

MAO activity returns completely back to normal after 24 hours of the last dose, which allows for a quick switch to another antidepressant after the 24 hours.[92]

Pharmacokinetics

In humans moclobemide is rapidly and almost completely absorbed and totally metabolised via the liver. Peak plasma levels occur 0.3 to 2 hours after oral administration. The bioavailability increases during the first week of therapy from 60% to 80% and more. The elimination half-life is around 2 hours.[92] [110] It is moderately bound to plasma proteins, especially albumin.[92] However, the short disposition half life somewhat increases after repeated dosing; moclobemide has an intermediate elimination half life for systemic clearance and an intermediate volume of distribution.[111] Despite its short half-life the pharmacodynamic action of a single dose persists for approximately 16 hours. The drug is almost completely metabolized in the liver; it is a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2.[112] Less than 1 percent of the drug is excreted unchanged; 92 percent of the metabolised drug is excreted within the first 12 hours.[113] The main metabolites are the N-oxide Ro 12-5637 formed via morpholine N-oxidation and lactam derivative Ro 12-8095 formed via morpholine C-oxidation;[114] [115] active metabolites are found only in trace amounts. The unchanged drug (less than 1%) as well as the metabolites are excreted renally (in urine). The main degradation pathway of moclobemide is oxidation.[116] About 44 percent of the drug is lost due to the first pass effect through the liver.[117] Age and renal function do not affect the pharmacokinetics of moclobemide. However, patients with significantly reduced liver function require dose reductions due to the significant slowing of metabolism of moclobemide.[118] Food slows the absorption but does not affect the bioavailability of moclobemide.[92]

Steady state concentrations are established after one week.[111] It has been suggested that changes in dose should not be made with a gap of less than a week.[119] Moclobemide has good penetration across the blood brain barrier with peak plasma levels within the central nervous system occurring 2 hours after administration.[120]

Animal toxicology

History

Irreversible MAOI antidepressants were discovered accidentally in the 1950s but their popularity declined as their toxicity especially their dangerous food interactions became apparent and rival tricyclic antidepressants were discovered. Reversible MAOIs were developed in the hope that they would exert efficacy in depressive disorders but with less of the toxicity of the older irreversible compounds; moclobemide's discovery and marketing brought the renewed interest in MAOIs due to an absence of dangerous tyramine food interactions and potent antidepressant effects.[121] [122] In 1992 moclobemide was launched onto the world markets.[123] Moclobemide was the first reversible MAO-A inhibitor to be widely marketed.[124] Moclobemide as well as other newer antidepressants such as the SSRIs led to changes in prescribing patterns and broadened the treatment options for the management of depressive disorders.[125]

When moclobemide was discovered in 1972 in Switzerland,[33] it was first hypothesized as being an antilipaemic or antibiotic, but the screenings were negative. The search for its antidepressant qualities, based on anticholinergic tests, also proved negative and moclobemide was then suspected of being an antipsychotic before its specific and reversible MAO-A inhibition qualities were detected. After the establishment of its lack of relevant interference with tyramine pressure response, clinical trials were launched in 1977 and further trials confirmed the broad antidepressant activity of RIMAs.[126] It was first approved in the UK and Europe as the first reversible and selective inhibitor of MAO-A and is now approved in over 50 countries worldwide.[33] Subsequent research found that moclobemide is well tolerated in elderly patients[127] and far superior to tricyclic antidepressants in terms of side effects, tolerability and overdose. With regard to effectiveness in the treatment of depression, moclobemide was determined to be as effective as all major antidepressant drug classes. There is no need for dietary restrictions in contrast to people on irreversible MAOIs and apart from an important interaction with other serotonergic enhancing agents such as SSRIs and pethidine, there are few serious drug interactions and because of these benefits, moclobemide became regarded as a beneficial addition to medical 'prescribing arsenal'.[70] [128] Additionally moclobemide was found, unlike most other antidepressants on the market, to actually improve all aspects of sexual function.[129] It is the only reversible MAOI in use in clinical practice.[92] The fact that moclobemide's pharmacokinetic properties are unaltered by age, that cognition is improved in the elderly, and moclobemide has low potential for food and drug interactions opened up a new avenue for the treatment of major depressive disorder.[92] Due to a lack of financial incentive, such as the costs of conducting the necessary trials to gain approval, moclobemide is unavailable in the USA pharmaceutical market.[33] In 2016 moclobemide was discontinued in Brazil for commercial reasons.[130]

Society and culture

The Australian TGA approved moclobemide in December 2000.[60]

Brands

It is sold under many trade names worldwide.[131]

It is sold under many trade names worldwide including Apo-Moclob, Apo-Moclobemide, Auromid, Aurorix, Bei Su, Biorix, Depnil, Eutac, Hai Bei Lin, Langtian, Manerix, Mobemid, Moclamine, Moclo A, Moclobemid - 1 A Pharma, Moclobemid AL, Moclobemid HEXAL, Moclobemid ratiopharm, Moclobemida, Moclobemida Genedec, Moclobemida Teva, Moclobemide Actavis, Moclobemide Aurobindo, Moclobemide CF, Moclobemide Mylan, Moclobemide Sandoz, Moclobemide Sopharma, Moclobemide Teva, Moclobemid-neuraxpharm, Moclobemid-ratiopharm, Moclobeta, Moclod, moclodura, Moclostad, Mocrim, Moklar, Teva-Moclobemide, Tian Tai, Ya Zheng, and Zorix.

See also

Further reading

Notes and References

  1. Web site: Anvisa . Brazilian Health Regulatory Agency . 2023-03-31 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 2023-08-03 . 2023-08-16 . . pt-BR . 2023-04-04.
  2. Schoerlin MP, Mayersohn M, Korn A, Eggers H . Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects . Clinical Pharmacology and Therapeutics . 42 . 4 . 395–404 . October 1987 . 3665338 . 10.1038/clpt.1987.169 . 46130982 .
  3. Freeman H . Moclobemide . Lancet . 342 . 8886–8887 . 1528–1532 . December 1993 . 7902906 . 10.1016/S0140-6736(05)80090-X . 208793357 .
  4. Gex-Fabry M, Balant-Gorgia AE, Balant LP . Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide . Therapeutic Drug Monitoring . 17 . 1 . 39–46 . February 1995 . 7725375 . 10.1097/00007691-199502000-00007 . 7044652 .
  5. Scheen AJ . [Drug of the month. Moclobemide (Aurorix)] . fr . Revue Médicale de Liège . 49 . 5 . 291–292 . May 1994 . 8023056 .
  6. Book: Cesura AM, Pletscher A . Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progres des Recherches Pharmaceutiques . Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques . The new generation of monoamine oxidase inhibitors . 38 . 171–297 . 1992 . 1609114 . 10.1007/978-3-0348-7141-9_3. 978-3-0348-7143-3 .
  7. Amrein R, Hetzel W, Stabl M, Schmid-Burgk W . RIMA--a new concept in the treatment of depression with moclobemide . International Clinical Psychopharmacology . 7 . 3–4 . 123–132 . January 1993 . 8468432 . 10.1097/00004850-199300730-00001 . 41433853 .
  8. Mitchell PB, Mitchell MS . The management of depression. Part 2. The place of the new antidepressants . Australian Family Physician . 23 . 9 . 1771–3, 1776–81 . September 1994 . 7980178 .
  9. Lecrubier Y, Guelfi JD . Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression . Acta Psychiatrica Scandinavica. Supplementum . 360 . 18–23 . 1990 . 2248063 . 10.1111/j.1600-0447.1990.tb05319.x . 25480681 .
  10. Angst J, Amrein R, Stabl M . Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies . Journal of Clinical Psychopharmacology . 15 . 4 Suppl 2 . 16S–23S . August 1995 . 7593725 . 10.1097/00004714-199508001-00004 .
  11. Priest RG, Gimbrett R, Roberts M, Steinert J . Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders . Acta Psychiatrica Scandinavica. Supplementum . 386 . 40–43 . 1995 . 7717094 . 10.1111/j.1600-0447.1995.tb05923.x . 25115362 .
  12. Spoov J, Suominen JY, Lahdelma RL, Katila H, Kymäläinen O, Isometsä E, Liukko H, Auvinen J . 6 . Do reversed depressive symptoms occur together as a syndrome? . Journal of Affective Disorders . 27 . 2 . 131–134 . February 1993 . 8440808 . 10.1016/0165-0327(93)90086-Y .
  13. Angst J, Scheidegger P, Stabl M . Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale . Clinical Neuropharmacology . 16 . Suppl 2 . S55–S62 . 1993 . 8313398 .
  14. Woggon B . The role of moclobemide in endogenous depression: a survey of recent data . International Clinical Psychopharmacology . 7 . 3–4 . 137–139 . January 1993 . 8468434 . 10.1097/00004850-199300730-00003 . 25765092 .
  15. Silverstone T . Moclobemide--placebo-controlled trials . International Clinical Psychopharmacology . 7 . 3–4 . 133–136 . January 1993 . 8468433 . 10.1097/00004850-199300730-00002 . 30905866 .
  16. Philipp M, Kohnen R, Benkert O . A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction . International Clinical Psychopharmacology . 7 . 3–4 . 149–153 . January 1993 . 8468436 . 10.1097/00004850-199300730-00005 . 19429752 .
  17. Tikal K, Hrabánková M . [Indications for antidepressive agents in relation to diseases of the cardiovascular system] . cs . Ceskoslovenska Psychiatrie . 89 . 3 . 163–165 . June 1993 . 8353831 .
  18. Delini-Stula A, Mikkelsen H, Angst J . Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies . Journal of Affective Disorders . 35 . 1–2 . 21–30 . October 1995 . 8557884 . 10.1016/0165-0327(95)00034-K .
  19. Stabl M, Biziére K, Schmid-Burgk W, Amrein R . Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states . Journal of Neural Transmission. Supplementum . 28 . 77–89 . 1989 . 2677244 .
  20. Versiani M, Nardi AE, Figueira I . Pharmacotherapy of dysthymia: review and new findings . European Psychiatry . 13 . 4 . 203–209 . July 1998 . 19698626 . 10.1016/S0924-9338(98)80005-9 . 7786359 .
  21. Nutt D, Montgomery SA . Moclobemide in the treatment of social phobia . International Clinical Psychopharmacology . 11 . 3 . 77–82 . June 1996 . 8923114 . 10.1097/00004850-199606000-00013 . 2463856 . free .
  22. Blanco C, Bragdon LB, Schneier FR, Liebowitz MR . The evidence-based pharmacotherapy of social anxiety disorder . The International Journal of Neuropsychopharmacology . 16 . 1 . 235–249 . February 2013 . 22436306 . 10.1017/S1461145712000119 . free .
  23. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine . The British Journal of Psychiatry . 161 . 3 . 353–360 . September 1992 . 1393304 . 10.1192/bjp.161.3.353 . 45341667 .
  24. Versiani M, Amrein R, Montgomery SA . Social phobia: long-term treatment outcome and prediction of response--a moclobemide study . International Clinical Psychopharmacology . 12 . 5 . 239–254 . September 1997 . 9466158 . 10.1097/00004850-199709000-00001 . 7144850 .
  25. Book: Rossi S . 978-0-9805790-9-3 . Australian Medicines Handbook . Adelaide . The Australian Medicines Handbook Unit Trust . 2013 . 2013 .
  26. Bonnet U . Moclobemide: therapeutic use and clinical studies . CNS Drug Reviews . 9 . 1 . 97–140 . 2003 . 12595913 . 6741704 . 10.1111/j.1527-3458.2003.tb00245.x .
  27. Berlin I, Saïd S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, Lecrubier Y, Puech AJ . 6 . A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers . Clinical Pharmacology and Therapeutics . 58 . 4 . 444–452 . October 1995 . 7586937 . 10.1016/0009-9236(95)90058-6 . 25252395 .
  28. Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N . Antidepressants for smoking cessation . The Cochrane Database of Systematic Reviews . 2023 . 5 . CD000031 . May 2023 . 37230961 . 10.1002/14651858.CD000031.pub6 . 10207863 . Cochrane1 .
  29. Tiller JW, Bouwer C, Behnke K . Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder . International Clinical Psychopharmacology . 12 . Suppl 6 . S27–S30 . October 1997 . 9466172 . 10.1097/00004850-199710006-00006 . 23852733 .
  30. Heymann RE, Paiva E, Helfenstein M, Pollak DF, Martinez JE, Provenza JR, Paula AP, Althoff AC, Souza EJ, Neubarth F, Lage LV, Rezende MC, de Assis MR, Lopes ML, Jennings F, Araújo RL, Cristo VV, Costa ED, Kaziyama HH, Yeng LT, Iamamura M, Saron TR, Nascimento OJ, Kimura LK, Leite VM, Oliveira J, de Araújo GT, Fonseca MC . 6 . Brazilian consensus on the treatment of fibromyalgia . Revista Brasileira de Reumatologia . 50 . 1 . 56–66 . 2010 . 21125141 . 10.1590/S0482-50042010000100006 . free .
  31. Liebowitz MR, Hollander E, Schneier F, Campeas R, Welkowitz L, Hatterer J, Fallon B . Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders . Acta Psychiatrica Scandinavica. Supplementum . 360 . 29–34 . 1990 . 2248064 . 10.1111/j.1600-0447.1990.tb05321.x . 30319319 .
  32. Menkes DB, Thomas MC, Phipps RF . Moclobemide for menopausal flushing . Lancet . 344 . 8923 . 691–692 . September 1994 . 7915384 . 10.1016/S0140-6736(94)92131-8 . 43226134 .
  33. Lotufo-Neto F, Trivedi M, Thase ME . Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression . Neuropsychopharmacology . 20 . 3 . 226–247 . March 1999 . 10063483 . 10.1016/S0893-133X(98)00075-X . 13181486 . free .
  34. Baumann P . Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors . Clinical Pharmacokinetics . 31 . 6 . 444–469 . December 1996 . 8968657 . 10.2165/00003088-199631060-00004 . 31923953 .
  35. Kennedy SH . Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors . Journal of Psychiatry & Neuroscience . 22 . 2 . 127–131 . March 1997 . 9074307 . 1188835 .
  36. Hill S, Yau K, Whitwam J . MAOIs to RIMAs in anaesthesia--a literature review . Psychopharmacology . 106 . Suppl . S43–S45 . 1992 . 1546140 . 10.1007/bf02246234 . 11555131 .
  37. Blom-Peters L, Lamy M . Monoamine oxidase inhibitors and anesthesia: an updated literature review . Acta Anaesthesiologica Belgica . 44 . 2 . 57–60 . 1993 . 8237297 .
  38. Alevizos B, Hatzimanolis J, Markianos M, Stefanis CN . Clinical, endocrine and neurochemical effects of moclobemide in depressed patients . Acta Psychiatrica Scandinavica . 87 . 4 . 285–290 . April 1993 . 8488751 . 10.1111/j.1600-0447.1993.tb03373.x . 7859228 .
  39. Chan-Palay V . Depression and senile dementia of the Alzheimer type: a role for moclobemide . Psychopharmacology . 106 . Suppl . S137–S139 . 1992 . 1546130 . 10.1007/bf02246259 . 22599717 .
  40. De Vanna M, Kummer J, Agnoli A, Gentili P, Lorizio A, Anand R . Moclobemide compared with second-generation antidepressants in elderly people . Acta Psychiatrica Scandinavica. Supplementum . 360 . 64–66 . 1990 . 2248077 . 10.1111/j.1600-0447.1990.tb05335.x . 25514792 .
  41. Tiller JW . Post-stroke depression . Psychopharmacology . 106 . Suppl . S130–S133 . 1992 . 1546128 . 10.1007/bf02246257 . 7694939 .
  42. Wesnes K, Anand R, Lorscheid T . Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia . Acta Psychiatrica Scandinavica. Supplementum . 360 . 71–72 . 1990 . 2248080 . 10.1111/j.1600-0447.1990.tb05338.x . 43677453 .
  43. Guentert TW, Banken L, Hilton S, Holford NH . Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events . Journal of Clinical Psychopharmacology . 15 . 4 Suppl 2 . 84S–94S . August 1995 . 7593736 . 10.1097/00004714-199508001-00014 .
  44. Swinkels JA, de Jonghe F . Safety of antidepressants . International Clinical Psychopharmacology . 9 . Suppl 4 . 19–25 . January 1995 . 7622819 . 10.1097/00004850-199501004-00003 . 37450365 .
  45. Priest RG, Baldwin DS, Bullock T, Kibel D, Smeyatsky N, Steinert J . Recent advances in antidepressant drugs . South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde . Suppl. Suppl . 1–4 . June 1992 . 1609337 .
  46. Moll E, Neumann N, Schmid-Burgk W, Stabl M, Amrein R . Safety and efficacy during long-term treatment with moclobemide . Clinical Neuropharmacology . 17 . Suppl 1 . S74–S87 . 1994 . 7954486 . 10.1097/00002826-199417001-00009 . 33885246 .
  47. Versiani M, Nardi AE, Figueira IL, Stabl M . Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo . Acta Psychiatrica Scandinavica. Supplementum . 360 . 24–28 . 1990 . 2123366 . 10.1111/j.1600-0447.1990.tb05320.x . 46436750 .
  48. Fitton A, Faulds D, Goa KL . Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness . Drugs . 43 . 4 . 561–596 . April 1992 . 1377119 . 10.2165/00003495-199243040-00009 . 195671164 .
  49. Amrein R, Hetzel W, Stabl M, Schmid-Burgk W . RIMA: a safe concept in the treatment of depression with moclobemide . Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie . 37 . Suppl 1 . 7–11 . September 1992 . 1394030 .
  50. Norman TR, Burrows GD . A risk-benefit assessment of moclobemide in the treatment of depressive disorders . Drug Safety . 12 . 1 . 46–54 . January 1995 . 7741983 . 10.2165/00002018-199512010-00004 . 37305194 .
  51. Hindmarch I, Kerr J . Behavioural toxicity of antidepressants with particular reference to moclobemide . Psychopharmacology . 106 . Suppl . S49–S55 . 1992 . 1546141 . 10.1007/bf02246236 . 27815494 .
  52. Alderman CP, Callary JA, Kent AL . Peripheral oedema associated with moclobemide . The Medical Journal of Australia . 157 . 2 . 144 . July 1992 . 1630391 . 10.5694/j.1326-5377.1992.tb137069.x .
  53. Tiller JW, Johnson GF, Burrows GD . Moclobemide for depression: an Australian psychiatric practice study . Journal of Clinical Psychopharmacology . 15 . 4 Suppl 2 . 31S–34S . August 1995 . 7593727 . 10.1097/00004714-199508001-00006 .
  54. Rimón R, Jääskeläinen J, Kaartinen P, Kalli A, Kilponen E, Koskinen T, Nikkilä H, Pirttiperä V, Seppälä J . 6 . Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study . International Clinical Psychopharmacology . 7 . 3–4 . 141–147 . January 1993 . 8468435 . 10.1097/00004850-199300730-00004 . 41323843 .
  55. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group . Journal of Affective Disorders . 28 . 2 . 105–116 . June 1993 . 8354766 . 10.1016/0165-0327(93)90039-M .
  56. Gram LF . [Antidepressive drug therapy, suicidal tendency and suicide, 2 cases reported in connection with moclobemide (Aurorix) therapy] . da . Ugeskrift for Laeger . 156 . 38 . 5542 . September 1994 . 7941097 .
  57. Isacsson G, Holmgren P, Druid H, Bergman U . The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994 . Acta Psychiatrica Scandinavica . 96 . 2 . 94–100 . August 1997 . 9272192 . 10.1111/j.1600-0447.1997.tb09912.x . 32663665 .
  58. Curran S, de Pauw K . Selecting an antidepressant for use in a patient with epilepsy. Safety considerations . Drug Safety . 18 . 2 . 125–133 . February 1998 . 9512919 . 10.2165/00002018-199818020-00004 . 32592676 .
  59. Bisserbe JC, Lépine JP . Moclobemide in social phobia: a pilot open study. GRP Group. Groupe de Recherche en Psychopharmacologie . Clinical Neuropharmacology . 17 . Suppl 1 . S88–S94 . 1994 . 7954487 . 10.1097/00002826-199417001-00010 . 27531475 .
  60. Web site: PRODUCT INFORMATION MOCLOBEMIDE SANDOZ® 150mg and 300mg TABLETS. TGA eBusiness Services. Sandoz. 16 October 2013. 6 March 2012.
  61. Web site: NAME OF THE DRUG AURORIX. TGA eBusiness Services. Meda Valeant Pharma Australia Pty Limited. 16 October 2013. 7 January 2013.
  62. Book: 978-0-85711-084-8 . British National Formulary (BNF) . Joint Formulary Committee . 2013 . Pharmaceutical Press . London, UK . 65 . registration .
  63. Zimmer R, Gieschke R, Fischbach R, Gasic S . Interaction studies with moclobemide . Acta Psychiatrica Scandinavica. Supplementum . 360 . 84–86 . 1990 . 2248085 . 10.1111/j.1600-0447.1990.tb05343.x . 46550463 .
  64. Tiller JW . Antidepressants, alcohol and psychomotor performance . Acta Psychiatrica Scandinavica. Supplementum . 360 . 13–17 . 1990 . 2248062 . 10.1111/j.1600-0447.1990.tb05318.x . 40365188 .
  65. Amrein R, Güntert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W . Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies . Psychopharmacology . 106 . Suppl . S24–S31 . 1992 . 1546135 . 10.1007/bf02246229 . 10570722 .
  66. Dingemanse J . An update of recent moclobemide interaction data . International Clinical Psychopharmacology . 7 . 3–4 . 167–180 . January 1993 . 8468439 . 10.1097/00004850-199300730-00008 . 11427093 .
  67. Duncan D, Sayal K, McConnell H, Taylor D . Antidepressant interactions with warfarin . International Clinical Psychopharmacology . 13 . 2 . 87–94 . March 1998 . 9669190 . 10.1097/00004850-199803000-00006 . 39487146 .
  68. Livingston MG, Livingston HM . Monoamine oxidase inhibitors. An update on drug interactions . Drug Safety . 14 . 4 . 219–227 . April 1996 . 8713690 . 10.2165/00002018-199614040-00002 . 46742172 .
  69. Hilton SE, Maradit H, Möller HJ . Serotonin syndrome and drug combinations: focus on MAOI and RIMA . European Archives of Psychiatry and Clinical Neuroscience . 247 . 3 . 113–119 . 1997 . 9224903 . 10.1007/BF03033064 . 25320878 .
  70. Tiller JW . Clinical overview on moclobemide . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 17 . 5 . 703–712 . September 1993 . 8255982 . 10.1016/0278-5846(93)90054-V . 8473676 .
  71. Zivanović O, Till E . [Serotonin syndrome--a case account] . Medicinski Pregled . 45 . 3–4 . 116–118 . 1992 . 16104086 .
  72. Spigset O, Mjörndal T, Lövheim O . Serotonin syndrome caused by a moclobemide-clomipramine interaction . BMJ . 306 . 6872 . 248 . January 1993 . 8443525 . 1676747 . 10.1136/bmj.306.6872.248 .
  73. Roxanas MG, Machado JF . Serotonin syndrome in combined moclobemide and venlafaxine ingestion . The Medical Journal of Australia . 168 . 10 . 523–524 . May 1998 . 9631680 . 10.5694/j.1326-5377.1998.tb141428.x .
  74. König F, Wolfersdorf M, Löble M, Wössner S, Hauger B . Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression . Pharmacopsychiatry . 30 . 4 . 125–127 . July 1997 . 9271778 . 10.1055/s-2007-979497 . 35570626 .
  75. Rolan P . Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90) . Cephalalgia . 17 . 18_suppl . 21–27 . October 1997 . 9399014 . 10.1177/0333102497017S1804 . 30479192 . Paul Rolan .
  76. Härtter S, Dingemanse J, Baier D, Ziegler G, Hiemke C . Inhibition of dextromethorphan metabolism by moclobemide . Psychopharmacology . 135 . 1 . 22–26 . January 1998 . 9489930 . 10.1007/s002130050481 . 19450106 .
  77. Web site: Moclobemide . go.drugbank.com . DrugBank online . 7 March 2021 . Accession Number DB01171.
  78. Lavian G, Finberg JP, Youdim MB . The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine . Clinical Neuropharmacology . 16 . Suppl 2 . S1–S7 . 1993 . 8313392 .
  79. Da Prada M, Zürcher G, Wüthrich I, Haefely WE . On tyramine, food, beverages and the reversible MAO inhibitor moclobemide . Journal of Neural Transmission. Supplementum . 26 . 31–56 . 1988 . 3283290 .
  80. Zimmer R . Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors . Acta Psychiatrica Scandinavica. Supplementum . 360 . 81–83 . 1990 . 2248084 . 10.1111/j.1600-0447.1990.tb05342.x . 9041656 .
  81. Heinonen EH, Myllylä V . Safety of selegiline (deprenyl) in the treatment of Parkinson's disease . Drug Safety . 19 . 1 . 11–22 . July 1998 . 9673855 . 10.2165/00002018-199819010-00002 . 9632549 .
  82. Korn A, Wagner B, Moritz E, Dingemanse J . Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline . European Journal of Clinical Pharmacology . 49 . 4 . 273–278 . 1996 . 8857072 . 10.1007/BF00226327 . 39823545 .
  83. Dingemanse J, Hussain Y, Korn A . Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide . International Journal of Clinical Pharmacology and Therapeutics . 34 . 4 . 172–177 . April 1996 . 8861736 .
  84. Hetzel W . Safety of moclobemide taken in overdose for attempted suicide . Psychopharmacology . 106 . Suppl . S127–S129 . 1992 . 1546127 . 10.1007/bf02246256 . 26798620 .
  85. Myrenfors PG, Eriksson T, Sandsted CS, Sjöberg G . Moclobemide overdose . Journal of Internal Medicine . 233 . 2 . 113–115 . February 1993 . 8433071 . 10.1111/j.1365-2796.1993.tb00662.x . 221919828 .
  86. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E . Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses . Lancet . 342 . 8884 . 1419 . December 1993 . 7901695 . 10.1016/0140-6736(93)92774-N . 39514927 .
  87. Isacsson G, Redfors I, Wasserman D, Bergman U . Choice of antidepressants: questionnaire survey of psychiatrists and general practitioners in two areas of Sweden . BMJ . 309 . 6968 . 1546–1549 . December 1994 . 7819894 . 2541721 . 10.1136/bmj.309.6968.1546 .
  88. Curtin F, Berney P, Kaufmann C . Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms . Journal of Psychopharmacology . 16 . 3 . 271–272 . September 2002 . 12236637 . 10.1177/026988110201600314 . 23038043 .
  89. Coupland NJ, Bell CJ, Potokar JP . Serotonin reuptake inhibitor withdrawal . Journal of Clinical Psychopharmacology . 16 . 5 . 356–362 . October 1996 . 8889907 . 10.1097/00004714-199610000-00003 .
  90. Ghanbarpour A, Hadizadeh F, Piri F, Rashidi-Ranjbar P . Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues . Pharmaceutica Acta Helvetiae . 72 . 2 . 119–122 . April 1997 . 9112832 . 10.1016/S0031-6865(97)00004-6 .
  91. Fulton B, Benfield P . Moclobemide. An update of its pharmacological properties and therapeutic use . Drugs . 52 . 3 . 450–474 . September 1996 . 8875133 . 10.2165/00003495-199652030-00013 . 195672909 .
  92. Nair NP, Ahmed SK, Kin NM . Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide . Journal of Psychiatry & Neuroscience . 18 . 5 . 214–225 . November 1993 . 7905288 . 1188542 .
  93. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M . 6 . Biochemistry and pharmacology of moclobemide, a prototype RIMA . Psychopharmacology . 106 . Suppl . S6-14 . 1992 . 1546143 . 10.1007/bf02246225 . 23563947 .
  94. Web site: Manerix Product Monograph . Valeant Canada LP . 30 June 2022 . 136.
  95. Sacher J, Houle S, Parkes J, Rusjan P, Sagrati S, Wilson AA, Meyer JH . Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study . Journal of Psychiatry & Neuroscience . 36 . 6 . 375–82 . November 2011 . 21463543 . 3201991 . 10.1503/jpn.100117 .
  96. Chiuccariello L, Cooke RG, Miler L, Levitan RD, Baker GB, Kish SJ, Kolla NJ, Rusjan PM, Houle S, Wilson AA, Meyer JH . 6 . Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors . The International Journal of Neuropsychopharmacology . 19 . 1 . pyv078 . August 2015 . 26316187 . 4772270 . 10.1093/ijnp/pyv078 . 138 .
  97. Lotufo-Neto F, Trivedi M, Thase ME . Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression . Neuropsychopharmacology . 20 . 3 . 226–247 . March 1999 . 10063483 . 10.1016/S0893-133X(98)00075-X . 13181486 . free .
  98. Cho HU, Kim S, Sim J, Yang S, An H, Nam MH, Jang DP, Lee CJ . 6 . Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis . Experimental & Molecular Medicine . 53 . 7 . 1148–1158 . July 2021 . 34244591 . 8333267 . 10.1038/s12276-021-00646-3 . 140 . 235786369 .
  99. Radat F, Berlin I, Spreux-Varoquaux O, Elatki S, Ferreri M, Puech AJ . Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study . Psychopharmacology . 127 . 4 . 370–376 . October 1996 . 8923574 . 10.1007/bf02806017 . 52872435 .
  100. Holford NH, Guentert TW, Dingemanse J, Banken L . Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor . British Journal of Clinical Pharmacology . 37 . 5 . 433–439 . May 1994 . 7519866 . 1364898 . 10.1111/j.1365-2125.1994.tb05710.x .
  101. Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ . Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects . Psychopharmacology . 106 . Suppl . S68–S70 . 1992 . 1546145 . 10.1007/bf02246239 . 22329953 .
  102. Haefely W, Burkard WP, Cesura A, Colzi A, Kettler R, Lorez HP, Martin JR, Moreau JL, Richards JG, Schaffner R . 6 . Pharmacology of moclobemide . Clinical Neuropharmacology . 16 . Suppl 2 . S8-18 . 1993 . 8313402 .
  103. Lin A, Song C, Kenis G, Bosmans E, De Jongh R, Scharpé S, Maes M . The in vitro immunosuppressive effects of moclobemide in healthy volunteers . Journal of Affective Disorders . 58 . 1 . 69–74 . April 2000 . 10760560 . 10.1016/S0165-0327(99)00076-2 .
  104. Mori S, Zanardi R, Popoli M, Garbini S, Brunello N, Smeraldi E, Racagni G, Perez J . 6 . cAMP-dependent phosphorylation system after short and long-term administration of moclobemide . Journal of Psychiatric Research . 32 . 2 . 111–115 . 1998 . 9694007 . 10.1016/S0022-3956(98)00003-X .
  105. Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE . Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors . Journal of Neural Transmission. Supplementum . 28 . 5–20 . 1989 . 2677242 .
  106. Markianos M, Alevizos V, Stefanis C . Plasma sex hormones and urinary biogenic amine metabolites during treatment of male depressed patients with the monoamine oxidase inhibitor moclobemide . Neuro Endocrinology Letters . 13 . 1 . 49–55 . 1991 . 0172-780X.
  107. Coquoz D, Porchet HC, Dayer P . Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers . Clinical Pharmacology and Therapeutics . 54 . 3 . 339–344 . September 1993 . 8375130 . 10.1038/clpt.1993.156 . 8229797 .
  108. Bitsios P, Langley RW, Tavernor S, Pyykkö K, Scheinin M, Szabadi E, Bradshaw CM . Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man . British Journal of Clinical Pharmacology . 45 . 6 . 551–558 . June 1998 . 9663810 . 1873648 . 10.1046/j.1365-2125.1998.00729.x .
  109. Vallès B, Coassolo P, De Sousa G, Aubert C, Rahmani R . In vitro hepatic biotransformation of moclobemide (Ro 11-1163) in man and rat . Xenobiotica; the Fate of Foreign Compounds in Biological Systems . 23 . 10 . 1101–1111 . October 1993 . 8259692 . 10.3109/00498259309059425 .
  110. Book: Leikin JB, Paloucek FP . Poisoning and toxicology handbook . 26 May 2009 . 4th . 2007 . Informa Health Care . 978-1-4200-4479-9 . 1331 . Moclobemide . https://books.google.com/books?id=0Bw2UJTC_uMC&q=moclobemide+half-life+elimination&pg=PA475 .
  111. Mayersohn M, Guentert TW . Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide . Clinical Pharmacokinetics . 29 . 5 . 292–332 . November 1995 . 8582117 . 10.2165/00003088-199529050-00002 . 25628650 .
  112. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K . Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study . Clinical Pharmacology and Therapeutics . 57 . 6 . 670–677 . June 1995 . 7781267 . 10.1016/0009-9236(95)90230-9 . 24783014 .
  113. Jauch R, Griesser E, Oesterhelt G, Arnold W, Meister W, Ziegler WH, Guentert TW . Biotransformation of moclobemide in humans . Acta Psychiatrica Scandinavica. Supplementum . 360 . 87–90 . 1990 . 2248086 . 10.1111/j.1600-0447.1990.tb05344.x . 41595227 .
  114. Härtter S, Dingemanse J, Baier D, Ziegler G, Hiemke C . The role of cytochrome P450 2D6 in the metabolism of moclobemide . European Neuropsychopharmacology . 6 . 3 . 225–230 . August 1996 . 8880082 . 10.1016/0924-977X(96)00023-5 . 34201446 .
  115. Gram LF, Brøsen K . Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group . British Journal of Clinical Pharmacology . 35 . 6 . 649–652 . June 1993 . 8329293 . 1381610 . 10.1111/j.1365-2125.1993.tb04196.x .
  116. Schoerlin MP, Guentert TW . [Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human] . de . Psychiatrische Praxis . 16 . Suppl 1 . 11–17 . August 1989 . 2685852 .
  117. Raaflaub J, Haefelfinger P, Trautmann KH . Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man . Arzneimittel-Forschung . 34 . 1 . 80–82 . 1984 . 6538424 .
  118. Goldberg RJ . Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide . Drugs & Aging . 11 . 2 . 119–131 . August 1997 . 9259175 . 10.2165/00002512-199711020-00004 . 24440475 .
  119. Guentert TW, Tucker G, Korn A, Pfefen JP, Haefelfinger P, Schoerlin MP . Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days . Acta Psychiatrica Scandinavica. Supplementum . 360 . 91–93 . 1990 . 2248087 . 10.1111/j.1600-0447.1990.tb05345.x . 8623387 .
  120. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ . Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects . British Journal of Clinical Pharmacology . 30 . 6 . 805–816 . December 1990 . 1705137 . 1368300 . 10.1111/j.1365-2125.1990.tb05445.x .
  121. Roth M, Guelfi JD . The efficacy of reversible monoamine oxidase inhibitors in depressive illness . Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie . 37 . Suppl 1 . 18–24 . September 1992 . 1394027 .
  122. Rudorfer MV . Monoamine oxidase inhibitors: reversible and irreversible . Psychopharmacology Bulletin . 28 . 1 . 45–57 . 1992 . 1609042 .
  123. Hilton S, Jaber B, Ruch R . Moclobemide safety: monitoring a newly developed product in the 1990s . Journal of Clinical Psychopharmacology . 15 . 4 Suppl 2 . 76S–83S . August 1995 . 7593735 . 10.1097/00004714-199508001-00013 .
  124. Volz HP, Gleiter CH, Möller HJ . [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge] . de . Der Nervenarzt . 67 . 5 . 339–347 . May 1996 . 9005342 .
  125. Mitchell PB, Mitchell MS . The management of depression. The place of the new antidepressants. Part 1. General overview . Australian Family Physician . 23 . 8 . 1555–9, 1562 . August 1994 . 7980156 .
  126. Angst J, Amrein R, Stabl M . Moclobemide: a paradigm of research in clinical psychopharmacology . International Clinical Psychopharmacology . 11 . Suppl 3 . 3–7 . June 1996 . 8923103 . 10.1097/00004850-199606003-00002 . 37604541 .
  127. Amrein R, Stabl M, Henauer S, Affolter E, Jonkanski I . Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview . Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie . 42 . 10 . 1043–1050 . December 1997 . 9469236 . 10.1177/070674379704201005 . 18651277 .
  128. Bech P . Acute therapy of depression . The Journal of Clinical Psychiatry . 54 . Suppl . 18–27; discussion 28 . August 1993 . 8253702 .
  129. Chebili S, Abaoub A, Mezouane B, Le Goff JF . [Antidepressants and sexual stimulation: the correlation] . fr . L'Encephale . 24 . 3 . 180–184 . 1998 . 9696909 .
  130. Web site: Aurorix®(moclobemida) - Meda. www.medapharma.com.br. pt-br. 2018-09-17.
  131. Web site: Moclobemide International Brands. Drugs.com. 3 June 2017.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Moclobemide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.